Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Palliative Care: What It Is and When To Use It

    Contains 2 Component(s) Recorded On: 08/20/2019

    Webinar hosted by the Public Health/Health Care Delivery Special Interest Group on August 20, 2019.

    Palliative care is specialized, interdisciplinary care that can be offered at any stage of a serious illness and focuses on symptom management, advance care planning, decision-making, psychosocial support, care coordination, and continuity of care. This webinar will assist clinicians in assessing basic palliative care needs in patients with liver disease as the disease progresses, offering clinical management strategies to address needs, and referring to specialty-level palliative care. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Lissi Hansen

    Dr. Hansen is a professor of nursing at Oregon Health and Science University. She studied nursing at Sankt Luksas Stiftelsen’s School of Nursing in Hellerup, Denmark. She received her Bachelor of Science in Nursing from Washington State University and master’s and PhD from Oregon Health and Science University. Dr. Hansen is one of the few researchers who studies patients with liver diseases including hepatocellular carcinoma (HCC) and their informal caregivers. She has an extensive clinical experience with acutely and chronically ill and dying patients and have palliative care training from the Harvard Medical School Center for Palliative Care.

    Dr. Hansen successfully co-authored and published several articles on her research as a principal investigator. She continues ongoing studies with the American Cancer Society MRSG, National Palliative Care Research Center, NIH/NINR and NIH/NCI. The long-term goal of her program of research is to develop interventions to improve symptom management and palliative care for patients with liver diseases and their families.

    Arpan Patel

    Dr. Patel is a transplant-trained hepatologist and health services researcher at the David Geffen School of Medicine at UCLA. He is also a staff physician at the West Los Angeles Veterans Affairs Center. He performed his residency in Internal Medicine at the Hospital of the University of Pennsylvania, followed by fellowship in gastroenterology at UCLA and fellowship in Transplant Hepatology at Mount Sinai.

    He is currently pursuing a PhD in Health Policy and Management at the Fielding School of Public Health at UCLA. Dr. Patel’s career goal is to ensure that patients with serious illnesses affecting the liver receive high-value care that optimizes their quality of life. His research goal is to understand ways that principles of palliative care can be integrated in management of these patients and their caregivers.

    Christopher Woodrell

    Dr. Woodrell is a health services researcher and board-certified internist and palliative care physician at the Icahn School of Medicine at Mount Sinai in New York City, where he is an appointed Assistant Professor. He is also Staff Physician within the Geriatric Research, Education and Clinical Center (GRECC) at the James J. Peters VAMC in the Bronx, NY. He received his Medical Doctorate, Internal Medicine Training, and Hospice and Palliative Medicine fellowship training at Mount Sinai.

    His career goal is to help improve quality of life experienced by people facing advanced liver disease and liver cancer. His research focus is developing and testing early palliative care interventions for people with hepatocellular carcinoma and their family caregivers. He completed undergraduate training in biochemistry at Swarthmore College in Pennsylvania.

    Mina Rakoski (Moderator)

    Mina Rakoski is a Transplant Hepatologist at Loma Linda University Health. She completed her medical education at Jefferson Medical College in Philadelphia, her residency at Cedars-Sinai Medical Center in Los Angeles and her Gastroenterology and Transplant Hepatology Fellowships at University of Michigan in Ann Arbor. During her time at University of Michigan, she attained her Master of Science in Health and Health Care Research through the Rackham Graduate School.

    Dr. Rakoski has a clinical and research interest in palliative care for patients with cirrhosis and hepatocellular carcinoma. She has a dual appointment in both Gastroenterology as well as Palliative Care at Loma Linda. She has started a hepatology palliative care clinic where she is able to provide integrated hepatology and palliative care services including in-office therapeutic paracentesis for patients with advanced liver disease. She is a co-investigator on a multicenter study funded by Patient-Centered Outcomes Research Institute (PCORI), which is investigating a novel approach of integrating palliative care into subspecialty clinics. She has written several review articles on palliative care in liver disease as well as presented on this topic at national conferences.

  • HBV Reactivation: How to Approach the Immunosuppressed Patient

    Contains 2 Component(s) Recorded On: 08/08/2019

    Webinar hosted by the Hepatitis B Special Interest Group on August 8, 2019.

    This webinar will review the latest approaches in the management of the immunosuppressed patient in the context of HBV reactivation, including screening, risk stratification and indication for antiviral treatment. The focus of management will be on both the oncologic and non-oncologic patient. The webinar will be organized as described below:

    Part 1: Management of the Cancer Patient

    Patients receiving cytotoxic chemotherapy
    Patients receiving monoclonal antibodies
    Patients undergoing hematopoietic stem cell transplant

    Part 2: Management of the Non-Cancer Patient

    Autoimmune based diseases: Rheumatologic, GI and dermatologic
    Reactivation in liver and non-liver solid organ transplantation
    HCV DAA Therapy

    We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Marina Nunez (Moderator)

    Marina Nunez, MD, PhD, is currently a Professor in the Department of Internal Medicine, sections on Infectious Diseases and on Gastroenterology at Wake Forest School of Medicine in Winston Salem, North Carolina. She received her MD and PhD from ‘Universidad de Navarra’ in Spain. She completed her Internal Medicine residency at ‘Clinica Universidad de Navarra’, and her fellowship in Infectious Diseases at Wake Forest University School of Medicine. She also obtained a degree in ‘Research Methodology and Design and Statistics in Health Sciences’. She is certified by the American Board in Internal Medicine and Infectious Diseases. She joined Wake Forest School of Medicine as faculty in 2006.

    Dr. Nunez has received several awards at her current institution for her contributions as educator, researcher and mentor. Her career has focused mainly on viral hepatitis, and she is internationally recognized for her work in HIV-co-infection. She is the author of more than 100 peer-reviewed articles, several book chapters and numerous abstracts and presentations reflecting her contribution to the field. Her expertise has led to the participation in national and international conferences, committees, and panels, as well as to the peer-review of numerous manuscripts for medical journals.

    Dr. Marina Nunez was a member of the NIH-CDC-HIVMA/IDSA Opportunistic Infections guidelines Hepatitis B Subject Group from 2010 to 2017. She currently serves on the Infectious Disease Society of America (IDSA) Standards and Practice Guidelines and on the AASLD Hepatitis B Special Interest Group's Education Subcommittee.

    Jessica Hwang

    Dr. Hwang is a professor in the Department of General Internal Medicine at The University of Texas MD Anderson Cancer Center. She has clinical and research experience in screening for and management of hepatitis B virus (HBV) in patients with cancer to facilitate early detection and interventions to reduce the risk of complications from immunosuppressive cancer therapy.

    She is a recipient of an NCI K07 Career Development Award and principal investigator of an NCI R21-funded prospective study comparing the effectiveness of widespread versus selective screening for HBV to prevent reactivation from cancer therapy; over 2000 patients were enrolled.

    She is a study chair of Southwest Oncology Group (SWOG) 1204 (PI: Scott Ramsey, MD, PhD), a national study to establish the seroprevalence of HBV, HCV, and HIV in patients with cancer at NCI Community Oncology Research Program cancer sites. She is the national PI of SWOG 1614, a multicenter randomized trial of prophylactic anti-HBV therapy in patients with HBV receiving anti-cancer therapy for solid tumors.

    Dr. Hwang is co-chair of the ASCO Provisional Clinical Opinion Committee on Hepatitis B Screening and am lead author of the panel’s 2015 updated recommendation. She is an invited member of the AASLD Hepatitis B Practice Guidelines Systematic Review and Writing Group; guideline recommendations were updated in 2015, also published guidance on HBV in 2018.

    She has published her work on screening and management of HBV in patients with cancer in Nature Reviews Gastroenterology and Hepatology, HEPATOLOGY, Journal of Clinical Oncology, Journal of Oncology Practice, among others.

    Hannah Lee

    Dr. Hannah Lee is an Assistant Professor of Medicine at Virginia Commonwealth University Medical Center in Richmond, VA in the Division of GI, Hepatology and Nutrition.

    She has a strong interest in liver cancer and viral hepatitis, particularly HBV. She was previously the Director of the Asian Pacific Liver Health Program in Boston Chinatown at Tufts Medical Center. She is currently Co-Director of the Multidisciplinary Liver Cancer Program at VCU and does both transplant and general hepatology. She is involved in multicenter studies evaluating the natural history of HBV and HCC.

    Her career has been focused on addressing health disparities in liver disease, particularly among disproportionately affected minority groups with chronic HBV. Some of her work has focused on screening and linkage to care. She has been involved in community research, education and outreach both locally and nationally in addressing liver health disparities in HBV and HCC among our various communities in the US.

    She currently serves on the AASLD Hepatitis B Special Interest Group's Leadership Steering Committee and is co-chair of the Education Subcommittee. She also serves as a committee member on the AASLD Public Policy Committee.

  • The 2018 Primary Biliary Cholangitis Practice Guidance: Highlights

    Product not yet rated Contains 2 Component(s) Recorded On: 07/25/2019

    Webinar recorded by the Cholestatic and Autoimmune Liver Diseases Special Interest Group on July 25, 2019.

    In this webinar, Drs. Marlyn Mayo and Cynthia Levy will discuss the most important recommendations included in the 2018 PBC Practice Guidance document. We will utilize a prerecorded webinar format for on-demand viewing on LiverLearning®.

    Cynthia Levy

    Cynthia Levy, MD, FAASLD is currently a Professor of Medicine in the Division of Hepatology at the University of Miami Miller School of Medicine. Dr. Levy received her MD from Universidade Federal do Rio de Janeiro, Brazil. She completed an Internal Medicine residency at University of Miami, a Gastroenterology Fellowship at Mayo Clinic, Rochester, and a Transplant Hepatology Fellowship at University of Florida, Gainesville, having received an AASLD Fellowship Award. Dr. Levy is a member of the AASLD Practice Guidelines Committee and of the ABIM Test and Policy Committee on Transplant Hepatology.  At the University of Miami, Dr. Levy is the program director for the Transplant Hepatology Fellowship program and Associate Director for the Schiff Center for Liver Diseases, where she conducts several industry-sponsored and investigator-initiated studies for cholestatic and autoimmune liver diseases.

    Marlyn Mayo

  • Early Liver Transplantation in Alcoholic Hepatitis

    Contains 2 Component(s) Recorded On: 07/24/2019

    Webinar hosted by the Alcoholic Liver Disease Special Interest Group on July 24, 2019.

    Alcoholic hepatitis has high short-term mortality with limited medical therapeutic options. Liver transplantation remains controversial for this indication given inability of these patients to meet six months of sobriety. Despite emerging data on early liver transplant as salvage therapy for severe alcoholic hepatitis, barriers remain on the acceptance of this option in the routine clinical care of these patients. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Alexandre Louvet

    Alexandre Louvet is professor of hepatology in the gastroenterology department of the University Hospital of Lille, France, headed by Prof. Philippe Mathurin. He earned his medical degree from the University of Lille. He received his PhD degree after a fellowship in the Institut Mondor de Recherche Biomédicale in Créteil, France, where he worked on the role of the endocannabinoid system in alcoholic liver disease in mice. His clinical interests include alcoholic liver disease, non-alcoholic fatty liver disease, hepatocellular carcinoma and viral hepatitis.

    He is involved in both clinical and basic research. His main topic in research is alcoholic hepatitis (natural history, treatment, disease modeling, transplantation, and pathophysiology). He has published several papers on the management of patients with severe alcoholic hepatitis. He is a member of the governing board of the French Association for the Study of the Liver (AFEF), of the editorial board of the Journal of Hepatology and a reviewer for several journals specialized in hepatology.

    Ashwani K. Singal

    Dr. Singal is an Associate Professor of Medicine at the University of South Dakota Sanford School of Medicine and Transplant Hepatologist at the Avera Transplant Institute. In addition, he also directs the hepatology elective course for the senior medical students at the Sanford Medical School and is Chief of Clinical Research Affairs at the Avera Transplant Institute. With clinical and translational research interests in alcoholic and non-alcoholic fatty liver diseases, renal injury in cirrhosis, and porphyria, Dr. Singal’s research has been funded by the American College of Gastroenterology, National Institute of Health, and pharmaceutical industry.

    He has over 160 original peer reviewed articles in national and international journals and book chapters. As an active executive member of the ACG practice parameters committee, Dr. Singal has developed practice guidelines for alcoholic liver disease and vascular disorders of the liver and currently involved in writing the guidelines on nutritional management of patients with cirrhosis. He also reviews research grants and scientific research abstracts for the AGA and AASLD. Dr. Singal is currently the Secretary and the Education subcommittee Chair of the Alcoholic Liver Disease Special Interest Group at AASLD.

    Thomas Schiano (Moderator)

    Dr. Thomas D. Schiano has a clinical background in hepatology, gastroenterology and clinical nutrition. He has expertise in the management of persons with cirrhosis and other acute/chronic liver diseases, and in caring for patients prior to and after liver transplantation. Dr. Schiano has varied clinical research interests including alcohol-related liver disease, nutritional aspects of liver disease, recurrence of disease post-liver transplantation, living donor liver transplantation, and management of the complications of cirrhosis. In addition, he is involved in the care of patients pre- and post-intestinal transplant. He is a member of the liver thrombosis program, an international referral center for adults and children with difficult to diagnose and unique blood clotting disorders affecting the liver and the intestines.

    Dr. Schiano is a UNOS-certified Liver Transplant physician, and is board certified in clinical nutrition, gastroenterology and transplant hepatology. Dr. Schiano completed fellowships in Hepatology and Liver Transplantation at The Mount Sinai Hospital, Gastroenterology at Temple University Hospital, and Clinical Nutrition at Memorial Sloan-Kettering Cancer Center. He completed a residency and chief residency in internal medicine at Maimonides Medical Center.

    Dr. Schiano is Professor of Medicine, Medical Director of Adult Liver Transplantation and Director of Clinical Hepatology at the Recanati/Miller Transplantation Institute. He is also Medical Director of the Intestinal Transplant program.

  • Challenges in Antiviral Therapy for Hepatitis C

    Contains 2 Component(s) Recorded On: 07/23/2019

    Webinar hosted by the Hepatitis C Special Interest Group on July 23, 2019.

    Management of HCV after therapy has complexity if patients continue to engage in high risk activities, are at risk for advanced liver disease progression or have failed first line therapy. In addition, these complexities are especially important to consider as HCV therapy moves outside of subspecialty care. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Stuart C. Gordon

    Dr. Gordon is a Professor of Medicine at Wayne State University School of Medicine and Director, Division of Hepatology, at Henry Ford Hospital. He received his training in clinical hepatology at the University of Miami, under Drs. Leon and Eugene Schiff. His major research interest is in the epidemiology and treatment of viral hepatitis. He has authored or coauthored over 200 papers, reviews and chapters, serves on several NIH Study Sections, and serves on the editorial board of Clinical Gastroenterology and Hepatology. Dr. Gordon is currently an appointed member of the AASLD-IDSA Hepatitis C Guidance Committee.

    In collaboration with the Centers for Disease Control, Dr. Gordon is the Principal Investigator of the multicenter CHeCS (Chronic Hepatitis Cohort Study) that examines the health burden, natural history, epidemiology and treatment challenges posed by chronic viral hepatitis in the United States. He also serves as Principal Investigator of the Fibrotic Liver Disease (FOLD) consortium of 11 US medical centers that collectively serve 4.2 million patients, and which examines the prevalence, natural history, treatment uptake/response, and clinical outcomes of patients with Primary Biliary Cholangitis (PBC) in the United States.

    Joseph Lim

    Dr. Lim is a Professor of Medicine in the Section of Digestive Diseases at Yale University, where he serves as Director of the Yale Viral Hepatitis Program. He is a graduate of the Feinberg School of Medicine at Northwestern University (Chicago, Illinois, USA), and completed training in Internal Medicine at Yale University (New Haven, Connecticut, USA), and Gastroenterology and Hepatology at Stanford University (Palo Alto, California, USA).

    In his role at the Yale Liver Center, he directs an active clinical trials program evaluating novel investigational agents for hepatitis B, hepatitis C, and NASH. He serves on the national EPIC Gastroenterology Specialty Steering Board, the steering committee of HCV-TARGET, and on the AASLD HCV SIG Steering Committee.

    Brian Pearlman

    Brian L. Pearlman, MD is Medical Director for Wellstar Atlanta Medical Center’s Center for Hepatitis C in Atlanta Georgia. He is also Professor of Medicine at the Medical College of Georgia and Professor of Medicine at Emory School of Medicine. Dr. Pearlman completed his medical degree at the University of Miami, Florida and his post-graduate training included both Diagnostic Radiology at University of Texas-Southwestern and Internal Medicine at Baylor University-Dallas, Texas.

    Dr. Pearlman is Faculty for the American College of Physicians (FACP) , Fellow of the American Association for the Study of Liver Diseases (FAASLD), and members of the American Academy of HIV Medicine, and the American Gastroenterological Association. He sat on the Board of Directors for The American Liver Foundation’s Southeast Chapter.

    Dr. Pearlman is widely published in leading journals such as The Lancet, Gastroenterology, HEPATOLOGY, The American Journal of Gastroenterology, The Lancet Infectious Disease, Clinical Infectious Diseases and The American Journal of Medicine. Dr. Pearlman is active in both patient care and in teaching physicians. He has been the recipient of numerous teaching awards, and also an active investigator in multiple hepatitis C-related trials, some of which are in collaboration with the CDC’s Division of Viral Hepatitis.

    Nancy Reau (Moderator)

    Dr. Nancy Reau is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center. Dr Reau’s research interest is in viral hepatitis drug development as well as utilization. She has authored or co-authored more than 100 peer-reviewed articles, invited reviews, editorials and online programs, as well as several book chapters, and two books. She is the editor-in-chief for Clinical Liver Disease, the AASLD multimedia journal. She was one of the original authors of the AASLD/IDSA hepatitis C guidance document.

    She is currently a member of the steering committee for the Hepatitis C Special Interest Group for the AASLD and is a member of the gastroenterology writing committee for the American Board of Internal Medicine.

  • Evaluation of Renal Dysfunction and Hyponatremia in Patients with Cirrhosis

    Contains 2 Component(s) Recorded On: 07/09/2019

    Webinar hosted by the Clinical Practice Special Interest Group on July 9, 2019.

    This webinar will discuss the management of renal insufficiency in patients with cirrhosis, in both the inpatient and outpatient settings. Topics to be discussed include workup of the patient with acute kidney injury in the outpatient setting, management of diuretics and evaluation using novel biomarkers. The audience member will be able to understand how to balance diuretics usage to account for symptom control versus patient safety, recognize the spectrum of etiologies of kidney dysfunction in the patient with cirrhosis and how to evaluate for them, and treatment of renal failure in the inpatient setting.  We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Josh Levitsky

    Josh Levitsky, MD, MS is currently a Professor of Medicine and Surgery in the Division of Gastroenterology & Hepatology at the Northwestern University Feinberg School of Medicine. Dr. Levitsky received his B.S. from the University of Michigan and M.D. from the Albert Einstein College of Medicine. He then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Chicago Hospitals and a Transplant Hepatology fellowship at the University of Nebraska Medical Center, receiving an AASLD Fellowship Award. He is currently certified by the American Board of Internal Medicine in Gastroenterology and Transplant Hepatology. At Northwestern, he completed a Master of Science in Clinical Investigation, is the Director of Liver Research, and is the program director for both Gastroenterology and Transplant Hepatology Fellowships. He has been elected to the Northwestern Feinberg Academy of Medical Educators and has received several teaching awards.

    Dr. Levitsky is an active member of several professional societies, including the American Society of Transplantation and International Liver Transplantation Society where he served on the executive boards, as well as the AASLD where he has served on several committees. He is a Deputy Editor for the American Journal of Transplantation and on the Editorial Board for HEPATOLOGY. Dr. Levitsky’s academic interests are clinical and translational in nature, with a focus on liver transplant immunosuppression, tolerance and biomarkers. He previously received an AASLD Career Development Award in Liver Transplantation and has published numerous peer-reviewed journal articles, abstracts, book chapters and reviews on topics relevant to liver disease and transplantation. He is the principal and co-investigator for a number of NIH, pharmaceutical and investigator-initiated trials. His goal is to advance clinical/translational research in immune-mediated liver diseases and liver transplantation, identifying biomarkers and novel strategies to optimize outcomes.

    Vinay Sundaram (Moderator)

    Dr. Vinay Sundaram is a transplant hepatologist at Cedars-Sinai Medical Center, where he serves as assistant medical director of liver transplantation and director of hepatology outcomes research. He has been a member of the AASLD since 2009. He is actively involved with numerous committees including the AASLD membership and mentorship committee, chair of the education subcommittee for the clinical practice special interest group.  In addition, he is on the membership and professional standards committee for UNOS. His research interests include end-stage liver disease, acute on chronic liver failure and post-transplant outcomes. He has over 100 published manuscripts and abstracts and is on the editorial board for Hepatology Communications. 

  • Clinical Hepatology Update On-Demand 2019

    Contains 37 Component(s), Includes Credits Recorded On: 06/14/2019

    Claim CME for the 2019 AASLD Clinical Hepatology Update.

    The Clinical Hepatology Update conference is designed for all medical professionals who manage care for patients with liver disease, including nurse practitioners, physician assistants, RNs, primary care physicians, medical students and GI or hepatology trainees. The conference will provide an update and review of the evolving practices in the clinical management of liver diseases.

    Core Competencies:  Patient Care and Procedural Skills Provide Patient-centered Care Values/Ethics for Interprofessional Practice Medical Knowledge Work in Interdisciplinary Teams Roles/Responsibilities Practice-based Learning and Improvement Employ Evidence-based Practice Interprofessional Communication Interpersonal and Communication Skills Apply Quality Improvement Teams and Teamwork Systems-based Practice

    Program Chairs:  Marcelo Kugelmas, MD, FAASLD Elizabeth K. Goacher, PA-C, MHS Janice Jou, MD, MHS  Lisa Catalli, MSN, NP-B

    CME Hours: 13.00 AMA PRA Category 1 Credits

    MOC Points: 13.00 MOC Points 

    Continuing Education (Nursing Credits): 13.00 Contact Hours

    Pharmacology: 1.25 Pharmacology Credits 

    All sessions must be viewed and all post-tests must be completed successfully to earn credits or points for this activity. Please note, no partial credits or points will be given.  

    Release Date: July 31, 2019
    Expiration Date: July 30, 2021


    Copyright: All faculty in this activity have given their permission for publication OR ©2019 AASLD

    Upon completion of this activity, learners will be able to: 

    To understand and describe the current standard of care for the diagnosis and management of non-alcoholic fatty liver disease.
    Manage patients with complications of portal hypertension.
    Recognize when decompensated cirrhosis patients are appropriate candidates for palliative care and hospice referral.

    Hepatologists
    Gastroenterologists
    Nurses
    Nurse Practitioners
    Physician Assistants
    Transplant Coordinators
    Fellows/Trainees 

    Jasmohan Bajaj, MD, FAASLD
    Bryan Balmadrid, MD
    Stephen Caldwell, MD, FAASLD
    Lisa Catalli, MSN, NP-BC
    Michael Chang, MD, MSc, MBA, FAASLD
    Kathleen Corey, MD, MPH, MMSc
    Khashayar Farsad, MD
    Jaquelyn Fleckenstein, MD, FAASLD
    Catherine Frenette, MD
    Richard Gilroy, MD
    Robert Gish, MD, FAASLD
    Elizabeth Goacher, PA-C, MHS
    Janice Jou, MD, MHS
    Marcelo Kugelmas, MD, FAASLD
    Jennifer Lai, MD
    Anne Larson, MD, FAASLD
    Michael Leise, MD
    Cynthia Levy, MD, FAASLD
    Willscott Naugler, MD, FAASLD
    Jody Olson, MD
    Arpan Patel, MD
    Sonali Paul, MD
    K Rajender Reddy, MD, FAASLD
    Puneeta Tandon, MD, FRCPC
    Elliot Tapper, MD
    Robert Weinrieb, MD

    Disclosures

    This enduring educational activity has been planned in accordance with AASLD and ACCME Standards of Commercial Support by members of the Clinical Hepatology Update faculty and the Clinical Research Committee and Governing Board.

    As an accredited provider, AASLD requires individuals involved in the planning of continuing medical education (CME) activities to disclose all financial relationships, including those of their spouse or partner, with a commercial interest within the past 12 months. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. All conflicts of interest are resolved prior to participation.

    Faculty Disclosures
    Jasmohan Bajaj, MD, FAASLD       
    Advisory Board and/or Committee and Review Panels: Valeant, Norgine, Intercept
    Honoraria for CME Activities: Integrity CE. CLD communications
    Grants/Research Support: Valeant 

    Bryan Balmadrid, MD          
    Nothing to disclose

    Stephen Caldwell, MD, FAASLD    
    Grant/Research Support: Genfit, TaiwanJ, Immuron, Gilead Sciences, Immuron, NGM, Mallinckrodt, Conatus, Galmed, Vital Therapy

    Lisa Catalli, MSN, NP-BC    
    Nothing to disclose 

    Michael Chang, MD, MSc, MBA, FAASLD 
    Nothing to disclose 

    Kathleen Corey, MD, MPH, MMSc  
    Speaking and Teaching: Synageva
    Scientific Consulting: Novo Nordisk

    Khashayar Farsad, MD        
    Scientific Consulting: Cook Medical, Neuwave Medical 
    Grants/Research Support: Guerbet, LLC Leadership in related society: American Society of Digestive Disease Interventions (consensus panel committee) 

    Jaquelyn Fleckenstein, MD, FAASLD       
    Nothing to disclose

    Catherine Frenette, MD       
    Scientific Consulting: Bayer, Intercept; Speakers Bureau: Bayer, Gilead

    Richard Gilroy, MD  
    Speakers Bureau: Novartis, Gilead, Salix

    Robert Gish, MD, FAASLD  
    Scientific Consulting: Abbot, AbbVie, Alexion, Arrowhead, Bayer AG, Bristol-Myers Squibb Company, Contravir, Eiger, Enyo, eStudySite, Genentech, Gilead Sciences, HepaTX, HepQuant, Hoffmann-LaRoche Ltd., Intellia, Intercept, Ionis Pharmaceuticals, Janssen, MedImmune, Merck, Shionogi, Transgene
    Trimaran Leadership in related society: AbbVie, Merck, Arrowhead, Bayer, Contravir, Dova Pharmaceuticals, Eiger, Enyo, Janssen, Medimmune, Janssen/J&J, Intercept, Shionogi, Spring Bank, Ionis
    Speakers Bureau: Alexion, Bayer, BMS, Dova, Gilead Sciences Inc., AbbVie, Merck

    Elizabeth Goacher, PA-C, MHS      
    Scientific Consulting: Gilead Pharmaceuticals, AbbVie Pharmaceuticals
    Speakers Bureau: AbbVie Pharmaceticals, Gilead Pharmaceuticals

    Janice Jou, MD, MHS          
    Nothing to disclose

    Marcelo Kugelmas, MD, FAASLD  
    Speakers Bureau: Intercept, Dova, Merck, Gilead, Abbvie, Salix
    Scientific Consulting: Gilead, Abbvie, Merck, Salix, Shinogi, Dova, Intercept, Mallinkrodt 
    Grants/Research Support: Novartis, Enanta, Tobira, Pfizer, Madrigal, Genfit, Shire, Cirius, Intercept, Dova, Gilead

    Jennifer Lai, MD       
    Scientific Consulting: Third Rock Ventures, LLC, Axcella

    Anne Larson, MD, FAASLD
    Nothing to disclose

    Michael Leise, MD    
    Nothing to disclose

    Cynthia Levy, MD, FAASLD
    Grants/Research Support: Intercept, Gilead, GSK, Novartis, Genfit, CymaBay, Enanta, Arena, Durect, High Tide, Eli Lilly
    Scientific Consulting: Target Pharma Solutions, Pliant, Cara Therapeutics
    Leadership in related society: Associate Editor- Liver Transplantation

    Willscott Naugler, MD, FAASLD     
    Nothing to disclose 

    Jody Olson, MD       
    Nothing to disclose 

    Arpan Patel, MD       
    Nothing to disclose

    Sonali Paul, MD        
    Nothing to disclose 

    K Rajender Reddy, MD, FAASLD   
    Grant/Research Support: AbbVie,Gilead, Janssen, Merck, Intercept, Mallinckrodt, Conatus, Novartis 

    Puneeta Tandon, MD, FRCPC        
    Advisory Committee and/or Review Panels: Lupin Pharma Canada 

    Elliot Tapper, MD     
    Grants/Research Support: Valeant, Gilead
    Scientific Consulting: Novartis

    Robert Weinrieb, MD           
    Nothing to disclose

    Planning Committee Disclosures
    Curtis K. Argo, MD, MS, FAASLD (Maintenance of Certification Committee)
    Nothing to disclose 

    Meena B. Bansal, MD, FAASLD (Governing Board)
    Nothing to disclose 

    Jorge A. Bezerra, MD, FAASLD (Governing Board)
    Grant/Research Support: Shyer, Gilead 

    Mamatha Bhat (Clinical Research Committee)
    Nothing to disclose 

    Therese Bittermann, MD (Clinical Research Committee)
    Nothing to disclose

    Kenneth D. Chavin, MD, PhD (Clinical Research Committee)
    Nothing to disclose

    Raymond Chung, MD, FAASLD (Governing Board; Maintenance of Certification Committee)
    Grant/Research Support: AbbVie, BMS, Merck, Boehringer Ingelheim, Gilead, Janssen
    Other: DSMB – Alnylam

    Laurie DeLeve, MD, PhD, FAASLD (Governing Board) 
    Consulting: Daiichi Sankyo; Seagen; Pfizer

    Edward Doo, MD (Clinical Research Committee) 
    Nothing to disclose

    Robert J. Fontana, MD, FAASLD (Clinical Research Committee)
    Grants/Research Support: BMS, Gilead, Abbvie
    Consulting: Sanofi

    Kimberly A Forde, MD, MHS (Clinical Research Committee)
    Nothing to disclose 

    Michael W. Fried, MD, FAASLD (Governing Board)
    Stock/Stock Options: TARGET PharmaSolutions Consulting: AbbVie, BMS, Merck, TARGET PharmaSolutions (All uncompensated)
    Grant/Research Support: AbbVie, BMS, Gilead, Merck, National Institutes of Health

    Debra Guss, DNP, RN, ANP-C (Maintenance of Certification Committee)
    Nothing to disclose

    Steven K. Herrine, MD, FAASLD (Maintenance of Certification Committee)
    Grant/Research Support: Gilead, BMS, Galectin, Intercept

    Vandana Khungar, MD, MSc (Maintenance of Certification Committee)
    Nothing to disclose

    Ayman A. Koteish, MD, FAASLD (Maintenance of Certification Committee)
    Nothing to disclose

    Paul Yien Kwo, MD, FAASLD (Clinical Research Committee) 
    Consulting: Gilead, Abbvie Grants/Research Support: BMS, Abbvie 

    John R. Lake, MD, FAASLD (Governing Board)
    Consulting: Vital Therapies, SRTR
    Other: Intercept DSMB

    Jennifer Cindy Lai, MD (Clinical Research Committee)
    Consulting: Third Rock Ventures, LLC, Axcella

    Rohit Loomba, MD (Clinical Research Committee)
    Grants/Research Support: Allergan, BMS, BI, Daiichi-Sankyo Inc., Galectin, Galmed, GE, Genfit, Gilead, Intercept, Janseen Inc, Madrigal, Merck, NGM, Pfizer, Prometheus, Siemens, Sirius
    Consulting: Bird Rock Bio, Celgene, Enanta, GRI Bio, Madrigal, Metacrine, NGM, Receptos, Sanofi, Arrowhead Research, Galmed, NGM, GIR, Inc. and Metacrine, Inc

    Bruce A. Luxon, MD, PhD, FAASLD (Governing Board)
    Board Membership: ACG Research Committee, Baxalta, DSMB
    Consulting: National Hemophilia Foundation 

    Lopa Mishra, MD, FAASLD (Governing Board)
    Grant/Research Support: NIH 

    Smruti R. Mohanty, MD, MS (Maintenance of Certification Committee)
    Leadership in related society: Education Committee Member, the Alliance for Academic Internal Medicine (AAIM) (July 2016-19) Editorial Board, World Journal of Gastroenterology (2007-Present) Editorial Board, Digestive Disease & Science (2009-Present) Editorial Board, World Journal of Hepatology (2009-Present) Reviewer: Hepatology, Clinical Gastroenterology & Hepatology, Digestive Disease & sciences, Post Graduate Medical Journal, World Journal of Gastroenterology World journal of hepatology
    Speaker's Bureau: Gilead Science, Merck, Abbvie and Intercept 

    David C. Mulligan, MD, FAASLD (Governing Board)
    Nothing to disclose 

    Arpan A. Patel, MD (Clinical Research Committee) 
    Nothing to disclose

    Heather M. Patton, MD, FAASLD (Maintenance of Certification Committee) 
    Grant/Research Support: Gilead Sciences 

    K. Gautham Reddy, MD, FAASLD (Maintenance of Certification Committee) 
    Leadership in related society: Board, Committee, Journal: Member, Training Committee: American College of Gastoneterology
    Speaker's Bureau: Intercept Dova;
    Research Grants: Merck Intercept Genfit 
    Scientific Consulting:  Advisor to Industry Commercial Enterprise, including Development of Educational Presentations: Intercept

    Susan M. Salahshor, PhD, PA-C (Clinical Research Committee)
    Nothing to disclose

    Ronald J. Sokol, MD, FAASLD (Governing Board)
    Consulting: Alexion; Albireo; Retrophin; Shire Grant/Research Support: Lumena/Shire; FFF Enterprises 

    Grace L. Su, MD, FAASLD (Maintenance of Certification Committee)
    Company Employee, Officer, Director: My husband and son have equity interest in Applied Morphomics and Prenovo

    Shikha Sundaram, MD, MSCI (Clinical Research Committee)
    Nothing to disclose

    Ryan M. Taylor, MD (Maintenance of Certification Committee)
    Speaker's Bureau: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Bristol-Myers Squibb, Merck, Inc., Abbvie, Inc.
    Grant/Research Support: Conatus Pharmaceuticals, Gilead Sciences, Abbvie, Conatus Pharmaceuticals 

    Norah Terrault, MD, MPH, FAASLD (Governing Board; Clinical Research Committee)
    Advisory Committees and/or Review Panels: Dova
    Grant/Research Support: AbbVie, Gilead, BMS, Merck 

    Kymberly Watt, MD (Clinical Research Committee)
    Other (eg. Expert testimony): Intercept - site- PI Gilead - site PI, co-I Conatus - site co-I Novartis - pr subanalysis Pfizer- site co-I all multicenter study related

    Julia J. Wattacheril, MD, MPH (Clinical Research Committee)
    Grants/Research Support: Conatus Pharmaceuticals, Genfit Pharmaceuticals, Galectin Therapeutics, Gilead Sciences, Intercept Pharmaceuticals

    Staff Disclosures
    Dominique Clayton 
    Nothing to disclose

    Katie Duggan
    Nothing to disclose

    Janeil Klett
    Nothing to disclose

    Denise Seise
    Nothing to disclose

    Anne Wrobel 
    Nothing to disclose 

    Amedco Staff Disclosures
    Sheryl Morgan
    Nothing to disclose


    Acknowledgement of Financial or In-Kind Commercial Support

    No financial or in-kind commercial support was received for this educational activity.

    Satisfactory completion 

    Participants must pass a post-test with a score of 70% or higher and complete an evaluation to receive a certificate of completion. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement. All sessions must be viewed and all post-tests must be completed successfully to earn credits or points for this activity. Please note, no partial credits or points will be given.  

    Credits Offered Continuing Medical Education (CME): 13.00 AMA PRA Category 1 Credits™; Maintenance of Certification (MOC): 13.00 MOC Points; Continuing Education (CE): 13.00 Contact Hours; Nurse Pharmacology Credits: 1.25 pharmacotherapeutic Credits..

    Accreditation and Designation Statements

    Continuing Medical Education (CME) The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 13.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

    Continuing Education (Nursing Contact Hours)  In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 13.00 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    Nurse Pharmacology Credits  The following presentations are also eligible for 1.25 pharmacotherapeutic hours:

    The Other Side of the Triad: Non-Cirrhotic Portal Hypertension Anticoagulation in Portal Hypertension Back to the Basics: Hepatitis B Management AIH: When to Change and If/When to Stop Therapy

    Please note onsite documentation for identification of sessions eligible for pharmacotherapeutic hours and self-submit those to your board. Keep the agenda as a reference in case they have questions.

    Claiming CME Credits Physicians and other health care professionals seeking 13.00 AMA PRA Category 1 Credits™ for this enduring continuing medical education activity must complete an evaluation by Friday, July 30, 2021

    Claiming ABIM MOC Points Physicians seeking ABIM and or ABP MOC points must complete the CME and MOC evaluation by Friday, July 30, 2021. Requests for MOC after this date will not be honored. The MOC evaluation is included in the CME evaluation.

    MOC Points will be reported to the ABIM and ABP by the end of each month through August 2021 for individuals who successfully complete the MOC evaluation.

    Claiming CE Contact Hours and Pharmacology Credits Nurses seeking a maximum of 13.00 contact hours or Nurses seeking up to 1.25 pharmacotherapeutic credits must complete an evaluation by Friday, July 30, 2021.

  • Clinical Hepatology Update Conference 2019

    Contains 26 Component(s) Recorded On: 06/14/2019

    Addressing Gaps in the Current Guidance: Assessing DILI with Novel Treatments or Preexisting Liver Disease in Clinical Trials

    ** VIEW ONLY CONTENT. The Clinical Hepatology Update 2019 enduring course will be available soon. It will be available under the "On-Demand Accredited Activities". **

    The Clinical Hepatology Update conference is designed for all medical professionals who manage care for patients with liver disease, including nurse practitioners, physician assistants, RNs, primary care physicians, medical students and GI or hepatology trainees. The conference will provide an update and review of the evolving practices in the clinical management of liver diseases.

    Core Competencies:  

    • Patient Care and Procedural Skills
    • Provide Patient-centered Care
    • Values/Ethics for Interprofessional Practice
    • Medical Knowledge
    • Work in Interdisciplinary Teams
    • Roles/Responsibilities
    • Practice-based Learning and Improvement
    • Employ Evidence-based Practice
    • Interprofessional Communication
    • Interpersonal and Communication Skills
    • Apply Quality Improvement
    • Teams and Teamwork
    • Systems-based Practice

    Program Chairs:

    Lisa Catalli, MSN, NP-B
    Elizabeth K. Goacher, PA-C, MHS
    Janice Jou, MD, MHS
    Marcelo Kugelmas, MD, FAASLD



    • To understand and describe the current standard of care for the diagnosis and management of non-alcoholic fatty liver disease.
    • Manage patients with complications of portal hypertension.
    • Recognize when decompensated cirrhosis patients are appropriate candidates for palliative care and hospice referral.  

    • Hepatologists 
    • Gastroenterologists    
    • Nurses
    • Nurse Practitioners    
    • Physician Assistants  
    • Transplant Coordinators
      Fellows/Trainees
  • HCV Treatment in Patients with IDU

    Product not yet rated Contains 2 Component(s) Recorded On: 05/21/2019

    Webinar hosted by the Hepatitis C Special Interest Group on May 21, 2019.

    Injection Drug Use (IDU) remains the leading risk factor for HCV.  Unfortunately, significant obstacles limit every aspect of the HCV care cascade in this population. This webinar will address the unique aspect of HCV and IDU and offer strategies to overcome existing limitations. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Jennifer Price

    Jennifer Price is an Associate Professor in the Department of Medicine and Division of Gastroenterology and Hepatology at the University of California, San Francisco (UCSF) and the Director of the UCSF Viral Hepatitis Center. Dr. Price leads the UCSF HCV Project Extension for Community Healthcare Outcomes (ECHO), a collaborative model of medical education and care management focused on building capacity for HCV care among primary care providers throughout Northern California. She launched UCSF’s first mobile liver clinical care unit, the DeLIVER Care Van, which aims to improve access to HCV screening and high-quality liver-related health care among medically and geographically marginalized communities. 

    Stacey Trooskin

    Stacey Trooskin, MD PhD, is the Director of Viral Hepatitis Programs at Philadelphia FIGHT Community Health Centers and Clinical Assistant Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania.  She received her MPH from Yale University School of Public Health, her medical degree from Robert Wood Johnson Medical School, and her PhD from Rutgers School of Public Health. She completed her internal medicine residency and infectious diseases fellowship at the Hospital of the University of Pennsylvania.

    Dr. Trooskin’s primary research interest focuses on health disparities and developing and evaluating innovative models of HCV testing and linkage to care. Dr. Trooskin serves at the Chief Medical Advisor to the National Viral Hepatitis Roundtable and is a member of the AASLD/IDSA HCV Guidelines Committee.  She is the Community Co-chair of the Hepatitis C Allies of Philadelphia (HepCAP) and the Principal Investigator of C Change: Philadelphia’s Plan to End Hepatitis C Among People Who Inject Drugs.

    Alain Litwin

    Dr. Alain Litwin is Vice Chair of Academics and Research and Professor of Medicine at Prisma Health, University of South Carolina School of Medicine – Greenville, and Clemson University School of Health Research where he leads a Center for Addiction and Prevention Research.  He is board certified in internal medicine and addiction medicine and has been providing medical care to people who use drugs with complex social, psychiatric and medical needs within an integrated primary care and substance use treatment program since 2000. 

    As HCV Medical Director at Albert Einstein’s Division of Substance Abuse, he developed a comprehensive on-site HCV treatment program and peer educator program to improve medical care of HCV-infected people who use drugs. As HCV Treatment Network Director at Montefiore Medical Center, he expanded patient-centered models of care at many community health centers serving thousands of HCV-infected people throughout the Bronx.  With funding from NIH, PCORI, CMS, CDC, AHRQ, Robert Wood Johnson Foundation, New York State Department of Health, New York City Department of Health, and industry, Dr. Litwin’s research has been focused on developing and studying models of addiction and medical care for people who inject drugs (PWID), and on advocating for increasing access to effective care for all PWID.  

    Dr. Litwin has worked with government and community organizations on efforts to expand access to HCV treatment and has collaborated on policy statements, clinical guidelines, treatment improvement protocols, task forces, and educational curricula with diverse stakeholders.  Dr. Litwin serves on the Executive Board for the International Network on Hepatitis in Substance Users (INHSU).

  • Management of NAFLD: Integrating Strategies from Obesity Medicine into Clinical Practice

    Contains 2 Component(s) Recorded On: 05/09/2019

    Webinar hosted by the NAFLD Special Interest Group on May 9, 2019.

    NAFLD is an increasing public health crisis. Although there are no FDA approved medications for the treatment of NAFLD, it is well established that weight loss can improve the metabolic and histologic parameters associated with NAFLD. This webinar will identify key lifestyle changes, pharmacotherapy, and the role of bariatric surgery in obesity management in patients with NAFLD. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Sonali Paul

    Sonali Paul is a transplant hepatologist and Assistant Professor of Medicine at the University of Chicago. She is also the director of the Metabolic and Fatty Liver clinic. She has an interest in non-alcoholic fatty liver disease, obesity medicine, organ allocation, health disparities, and shared decision making between patients and providers. She received an MD from Tufts University School of Medicine. She completed her internal medicine residency at Massachusetts General Hospital and returned to Tufts for her fellowship training in gastroenterology. She also earned an MS in clinical and translational science from the Sackler School of Graduate Biomedical Sciences at Tufts University. She completed an advanced hepatology fellowship at Massachusetts General Hospital in 2016 and joined the University of Chicago faculty shortly thereafter. 

    Stavra Xanthakos

    Dr. Xanthakos is a Professor of Pediatrics within the Division of Gastroenterology, Hepatology and Nutrition at Cincinnati Children’s Hospital Medical Center, with clinical and research expertise in the management of pediatric obesity and nonalcoholic fatty liver disease.  After receiving her MD degree from Duke University School of Medicine, she completed pediatric residency and fellowship training at Cincinnati Children’s.  She serves as the director of the Steatohepatitis Center, as well as the medical director of the Surgical Weight Loss Program for Teens, one of the largest adolescent bariatric surgery programs in the United States. She also collaborates with colleagues from Cardiology, Endocrinology and Psychology in a multidisciplinary behavioral weight management program for children affected by multiple obesity-related comorbid conditions.  She participates in several National Institute of Health-sponsored research consortia focused on children and adolescents with NAFLD and/or severe obesity, and also has received funding from the National Institutes of Health to investigate the outcomes of adolescents with NAFLD following bariatric surgery.